260 related articles for article (PubMed ID: 35256414)
1. Advances in immunotherapy for cervical cancer: recent developments and future directions.
Sherer MV; Kotha NV; Williamson C; Mayadev J
Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
[TBL] [Abstract][Full Text] [Related]
2. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
4. Advances in immunotherapy in cervical cancer.
Grau JF; Farinas-Madrid L; Garcia-Duran C; Garcia-Illescas D; Oaknin A
Int J Gynecol Cancer; 2023 Mar; 33(3):403-413. PubMed ID: 36878562
[TBL] [Abstract][Full Text] [Related]
5. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
[TBL] [Abstract][Full Text] [Related]
6. Evolving standards and future directions for systemic therapies in cervical cancer.
Ang DJM; Chan JJ
J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
[TBL] [Abstract][Full Text] [Related]
7. Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer.
Li Y; Shen F; Tan Q; Chen Y; Gu Y
Technol Cancer Res Treat; 2023; 22():15330338231208846. PubMed ID: 37908109
[TBL] [Abstract][Full Text] [Related]
8. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
9. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Giudice E; Mirza MR; Lorusso D
Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract][Full Text] [Related]
13. Advances in immunotherapy for cervical cancer.
Grau-Bejar JF; Garcia-Duran C; Garcia-Illescas D; Mirallas O; Oaknin A
Ther Adv Med Oncol; 2023; 15():17588359231163836. PubMed ID: 37007635
[TBL] [Abstract][Full Text] [Related]
14. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in immunotherapy of cancers caused by human papillomaviruses.
Fakhr E; Modic Ž; Cid-Arregui A
Immunology; 2021 May; 163(1):33-45. PubMed ID: 33205441
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
[TBL] [Abstract][Full Text] [Related]
18. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
García E; Ayoub N; Tewari KS
J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for cervical cancer: Can it do another lung cancer?
Ramanathan P; Dhandapani H; Jayakumar H; Seetharaman A; Thangarajan R
Curr Probl Cancer; 2018; 42(2):148-160. PubMed ID: 29500076
[TBL] [Abstract][Full Text] [Related]
20. Gearing up T-cell immunotherapy in cervical cancer.
Chauhan SR; Bharadwaj M
Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
